We are Sorry, This Page doesn't Exist

Biogen Inc revealed surprise plans to seek U.S. regulatory approval for its Alzheimer's treatment aducanumab on Tuesday, saying new analysis of clinical trials showed promise, just months after it had shelved two studies......»»

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 21.) read more.....»»

Biogen said it will pursue .....»»

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab......»»

Eisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orders after the Japanese drugmaker and its partner Biogen Inc said they are ending two drug trials of their experimental Alzheimer's disease drug aducanumab......»»

Brainstorm Health Daily: March 21, 2019 Good afternoon, readers. It was a sad day for biopharma. Yet again, an Alzheimer’s drug hopeful crashed and burned in critical late-stage clinical trials. The victim, this time, was biotech gian.....»»

Biogen Inc and partner Eisai C.....»»

Biogen scraps Alzheimer drug trials, wiping $17 billion off its market value.....»»

Biogen.....»»

Biogen shares plunged in pre-market trading Thursday after the biotech group dropped a late-stage trial for a key Alzheimer's disease drug......»»

Biogen and partner Eisai Co Ltd are ending two late-stage trials testing the experimental Alzheimer's drug aducanumab, marking the latest setback for an industry racing to develop treatments for the memory-robbing disease......»»

Biogen has lost over a quarter of its market cap in the pre-market after the biotech giant and partner Eisai decided to stop late-stage studies of their Alzheimer’s disease drug.....»»

Shares of neuroscience company Biogen Inc (NASDAQ: BIIB) lost more than 25 percent Thursday morning after the company said it will discontinue an ongoing Alzheimer read more.....»»

Biogen Inc. said early Tuesday that it will pay $50 million to privately-held Neurimmune to reduce royalty rates on the late-stage Alzheimer's disease drug aducanumab. The 5% reduction will leave royalty rates on potenti.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 5) read more.....»»

Shares of Biogen Inc (NASDAQ: BIIB) soared higher by more than 13 percent early Friday morning in reaction to the results of an Alzheimer's disease study.  read more.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Biogen gained billions of dollars in market value on Friday after announcing promising results from a trial of one of its experimental Alzheimer’s disease drugs, marking a rare dose of good news in the daunting field. Cambridge-based Biogen (Nasda.....»»

Biogen (BIIB) stock was soaring today on positive results from a recent Alzheimer's drug trial conducted along with Eisai......»»

Biogen and Japan’s Eisai sa.....»»